Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by El-Rayes, B. F.
Right arrow Articles by Philip, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by El-Rayes, B. F.
Right arrow Articles by Philip, P. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:960-965, 2004
© 2004 European Society for Medical Oncology

Original Paper

A phase II study of carboplatin and paclitaxel in esophageal cancer

Received 10 June 2003; revised 6 February 2004; accepted 17 February 2004

Background:

This study was conducted to evaluate the efficacy and toxicity of combination carboplatin and paclitaxel in patients with esophageal cancer.

Materials and methods:

Thirty-five patients were enrolled. Patients were treated with paclitaxel 200 mg/m2 intravenously (i.v.) over 3 h and carboplatin i.v. at an AUC of 5 mg/h/ml. Thirty-three patients were assessable for toxicity and objective response.

Results:

A total of 166 treatment courses were administered with a median of five courses per patient. The objective response rate was 43% [90% confidence interval (CI) 0.3–0.58] by the intention-to-treat analysis. The median response duration was 2.8 months (90% CI 2.1–5.4). The median survival time was 9 months (90% CI 7–13.8) and the 1-year survival rate was 43% (90% CI 0.29–0.57). The major grade 3–4 toxicity observed was neutropenia, occurring in 17 patients (52%). There were no treatment-related deaths.

Conclusions:

The combination of carboplatin and paclitaxel is an moderately active and tolerable regimen in advanced esophageal cancer.

B. F. El-Rayes, A. Shields, M. Zalupski, L. K. Heilbrun, V. Jain, D. Terry, A. Ferris and P. A. Philip*

Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

Key words: carboplatin, combination chemotherapy, esophageal cancer, paclitaxel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
W. Cao, C. Xu, G. Lou, J. Jiang, S. Zhao, M. Geng, W. Xi, H. Li, and Y. Jin
A Phase II Study of Paclitaxel and Nedaplatin as First-line Chemotherapy in Patients with Advanced Esophageal Cancer
Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 582 - 587.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.